TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (University Radiology Group, Rutgers Robert Wood Johnson University Hospital), who will join company management to discuss the unmet need and current treatment landscape for uterine fibroids. To register, click here.

The event will provide an overview of the TriNav Infusion System whose Pressure-Enabled Drug Delivery™ (PEDD™) approach helps to precisely target the tumor and facilitates deeper therapy penetration while protecting against non-target embolization1-3. The Company will also review the Uterine Artery Embolization (UAE) market landscape and opportunity for TriNav.

A live question and answer session will follow the formal presentations.

About Nicole Lamparello, MD

Nicole Lamparello, MD is a radiologist specializing in Vascular and Interventional Radiology. She is an Assistant Professor of Radiology at Weill Cornell Medicine and an Assistant Attending Radiologist at NewYork-Presbyterian Hospital/Weill Cornell Medicine. She also serves as program director for the Integrated IR Residency Program, and is heavily passionate about trainee education and molding the next generation of IRs. She is Co-Director for the Skills Acquisition and Innovation Laboratory at Weill Cornell Medicine and serves as Chair of Quality Improvement for Fibroid and Adenomyosis Center at Weill Cornell Medicine. Dr. Lamparello was recruited to join the Weill Cornell faculty after completing a fellowship in Vascular and Interventional Radiology at the Hospital of the University of Pennsylvania. Dr. Lamparello completed her residency in Diagnostic Radiology at New York University Langone Medical Center where she also finished an internship in Medicine. She earned her M.D. from New York University School of Medicine in 2012. Her interests and specialties include women’s health, uterine fibroid embolization, pelvic congestion syndrome, fallopian tube recanalization, percutaneous GU and GI interventions, dialysis interventions, as well as venous access and IVC filter placement and retrieval. Dr. Lamparello believes in a patient-centered approach to healthcare, working with patients to identify and meet their individual goals. She is compassionate, dedicated, and highly accessible to her patients.

About Francis Kang, MD

Francis Kang, MD is a partner radiologist at University Radiology Group. He currently serves as the Clinical Chief of Interventional Radiology at Rutgers Robert Wood Johnson University Hospital as well as the Faculty Advisor, Associate Program Director of Integrated IR Residency, and Associate Program Director of Independent IR Residency at Rutgers Robert Wood Johnson Medical School. Dr. Kang's journey is characterized by a commitment to excellence in patient care, education, and research, aligning seamlessly with the ethos of Rutgers Robert Wood Johnson Medical School. He completed his medical school training at Texas A&M Health Science Center College of Medicine followed by Radiology residency at Rutgers Robert Wood Johnson Medical School, where he served as a chief resident. Upon finishing his residency with ESIR (Early Specialization in IR) track, Dr. Kang completed his IR fellowship at University of Texas MD Anderson Cancer Center. His focus is on Interventional Oncology, with a primary focus on liver-directed therapy for Hepatocellular Carcinoma (HCC) and metastatic liver lesions. He contributes to advancing treatment options for patients facing these challenging conditions within the Gastrointestinal/Hepatobiliary Program at Rutgers Cancer Institute of New Jersey. Dr. Kang is also actively engaged in various clinical trials, showcasing a commitment to pushing the boundaries of medical knowledge and providing patients with access to innovative treatments.

About TriSalus Life Sciences

TriSalus Life Sciences^® is a growing, oncology focused medical technology business bringing disruptive drug delivery technology with the goal of improving therapeutic delivery for the treatment of both oncologic and non-oncologic conditions. Additionally, we are exploring the integration of our technology with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications. We have developed an innovative organ-specific platform that is designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (I) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) the immunosuppressive properties of liver and pancreatic tumor immune cells. By systematically addressing these barriers, we aim to improve response to therapies and to enable improved patient outcomes.

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “become,” “may,” “intend,” “will,” “expect,” “anticipate,” “believe” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding TriSalus’s business, the commercial potential of its TriNav Infusion System, TriSalus’s proprietary PEDD approach, the potential therapeutic benefits and commercial potential of Nelitolimod, and TriSalus’s technologies and other products in development. Such statements are subject to certain risks and uncertainties, including, but not limited to, those inherent in the process of developing and commercializing medical devices that are safe and effective for human use, discovering, developing and commercializing medicines that are safe and effective to use as human therapeutics, and the endeavor of building a business around such medical devices and medicines.

TriSalus’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although TriSalus’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by TriSalus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning TriSalus’s products and programs are described in additional detail in TriSalus’s annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission (the "SEC") and available at the SEC's website (www.SEC.gov). These forward-looking statements are made as of the date of this press release, and TriSalus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110470865/en/